Early Is Good

Early Is Good is redefining cancer diagnostics by addressing the critical blind spot of incomplete biological information. Their proprietary platform integrates three biological dimensions—DNA, RNA, and Proteins—from a single sample with attomolar sensitivity, eliminating the need for extraction or amplification. The company is advancing a pipeline of liquid biopsy tests, has secured significant seed funding and an NIH grant, and is collaborating with leading academic institutions to validate and commercialize its tests, beginning with applications in urologic oncology.

A proprietary diagnostic platform that simultaneously analyzes DNA, RNA, and Proteins from a single blood or urine sample with attomolar sensitivity, without the need for extraction or amplification.

Total raised: $2M

Competes against single-omic liquid biopsy leaders (e.g., Guardant Health, Exact Sciences) and other multi-omic/proteomic firms (e.g., Seer, Nautilus). Differentiation is claimed through the simultaneous, integrated analysis of DNA, RNA, and Protein from one sample without amplification, aiming for a more complete biological picture.